Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Status:
Recruiting
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial compares iberdomide maintenance therapy to disease monitoring for
improving survival in patients who have received idecabtagene vicleucel (a type of chimeric
antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The usual approach after
treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving
myeloma medications. There is currently no medication approved specifically for use after
idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system
and activates immune cells called T-cells, which could enhance the effectiveness of
idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than
the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple
myeloma patients live longer.